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ABSTRACT 
 
INTRODUCTION: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is 
an inherited pathology that can increase the risk of sudden death. Current Task Force 
Criteria for echocardiographic diagnosis do not include new, regional assessment 
tools which may be relevant in a phenotypically diverse disease. We adopted a 
systematic review and meta-analysis approach to highlight echocardiographic indices 
that differentiated ARVC patients and healthy controls. METHODS: Data was 
extracted and analysed from prospective trials that employed a case-control design 
meeting strict inclusion and exclusion as well as a-priori quality criteria. Structural 
indices included proximal RV outflow tract(RVOT1) and RV diastolic area(RVDarea). 
Functional indices included RV fractional area change (RVFAC), Tricuspid Annular 
Systolic Excursion(TAPSE), peak systolic and early diastolic myocardial velocities 
(S’ and E’ respectively) and myocardial strain. RESULTS: Patients with ARVC had 
larger RVOT1 (mean  SD; 34 vs. 28 mm P<0.001) and RVDarea (23 vs. 18 cm
2
 
P<0.001) compared to healthy controls. ARVC patients also had lower RVFAC (38 
vs. 46 % P<0.001), TAPSE(17 vs. 23 mm P<0.001), S’ (9 vs. 12 cm.s-1 P<0.001), E’ 
(9 vs. 13 cm.s
-1
 P<0.001) and myocardial strain (-17 vs. -30% P<0.001). 
CONCLUSION:The data from this meta-analysis support current Task Force criteria 
for the diagnosis of ARVC. In addition, other RV measures that reflect the complex 
geometry and function in ARVC clearly differentiated between ARVC and healthy 
controls and may provide additional diagnostic and management value. We 
recommend that future working groups consider this data when proposing new / 
revised criteria for the echocardiographic diagnosis of ARVC. 
 
INTRODUCTION 
Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC/D) is a genetic 
disease that is characterized by; 1) fibro-fatty replacement, 2) myocardial atrophy, 3) 
fibrosis, and 4) chamber dilation and aneurysms 
1
. Pathological changes occur 
predominantly in the right ventricle (RV) and culminate in heart failure 
1–3
 with 
sudden cardiac death (SCD) a common outcome 
1,2,4
. It is clearly important to identify 
those with ARVC as early as possible in order to treat and reduce health risk.  
The prevalence of ARVC in the general population has been reported to be 1:5000, 
affecting men more frequently than women with a ratio of 3:1 
5,6
. The accuracy of 
available prevalence data is, however, still debated largely due to the complexities in 
diagnosing the disease 
7
. Currently, the diagnosis of ARVC can be established using a 
set of major and minor criteria proposed by an International Task Force in 1994  and 
updated/revised in 2010 
8,9
. The structural and functional assessment of the RV, using 
transthoracic echocardiography, is central to ARVC diagnosis in the original and 
updated Task Force criteria.  Although the recent Task Force revision has improved 
specificity of diagnosis there has been little impact upon diagnostic sensitivity 
3
 which 
may be due to the reliance on only two RV anatomical measures (the RV outflow tract 
from a parasternal long [RVOTPLAX] and short axis [RVOT1] and one functional 
measure (RV fractional area change [RVFAC]). It is likely that these parameters do 
not fully reflect the complexities of RV structure and function specifically in ARVC 
where phenotype expression is variable 
1,10
 and regional changes in structure and 
function are likely. A more comprehensive echocardiographic assessment of the RV 
in ARVC patients is warranted 
11
 in order to potentially improve diagnostic accuracy.  
The use of techniques such as tissue Doppler imaging and speckle tracking 
echocardiography (STE), that quantifies regional myocardial deformation/strain have 
the potential to provide new information in ARVC 
12–14
.  Likely due to the low 
prevalence of the disease, these studies are often based on relatively small sample 
sizes that restrict generalizability to all populations 
14–16
. A qualitative assessment of 
recent research in this area highlights limitations such as a lack of a matched control 
group and variability in echocardiographic tools and techniques. To determine if new 
echocardiographic data may provide additional diagnostic options this study 
employed a systematic review (with clear quality control and inclusion/exclusion 
criteria) alongside a meta-analysis to determine which RV structural and functional 
parameters are different between patients with ARVC and matched, healthy control 
subjects.  
 
METHODS 
Search criteria and processes 
Study Selection 
We identified all transthoracic echocardiographic studies that examined ARVC 
patients and recorded parameters related to RV structure and/or function published 
between 1990 and 2015 and written with an English language abstract. Electronic 
search engines used included; Pub Med; Discover; Scopus; Web of Science; 
Cochrane, and we employed relevant Medical Subject Headings (MeSH) and 
keywords related to our search. The following search keyword strings were used:  
 Echocardiography AND (ARVC OR ARVD) AND (Arrhythmogenic Right 
Ventricular Cardiomyopathy OR Arrhythmogenic Right Ventricular 
Dysplasia). 
The initial search identiﬁed 966 records.  The first level of filtration included 
screening of titles, authors and abstracts and was completed independently by two 
reviewers (MQ, DO). In the case of discrepancy between reviewers a third 
independent reviewer was invited to feedback and subsequently a final review 
meeting was undertaken to determine a consensus opinion. Initial filtration removed 
case studies, duplications, reviews, animal studies as well as comparing the abstract 
against the following inclusion criteria; (1) genotype-positive ARVC patients, (2) age 
range 16–65 years, and (3) all participants had echocardiography and reported RV 
parameters 
17 
which matched description of the Task Force criteria 
8,9
. This filtration 
identified 45 studies for complete evaluation of the full research paper by the same 
two independent reviewers. These 45 papers were also subjected to a quality 
assessment using a check list modified by the research team from the PRISMA 
18
 and 
STROBE
 19
 statements, to develop the systematic evaluation of the quality of 
observational studies. A threshold of 40% adherence of the quality criteria checklist 
was adopted. From the 45 papers identified 19 were excluded based on incomplete 
data sets with abstract only, 12 due to lack of including both an ARVC and a control 
groups, 2 non-English manuscripts that were missed by the original filtration process, 
and 2 with poor overall quality scores. The remaining 10 papers were subject to full 
data extraction and meta-analysis. The overall ﬁltration process is detailed in Figure 1. 
 
INSERT FIGURE 1 
 Data Extraction 
Data extraction was undertaken by two investigators (MQ, DO) and where present 
included data for the following RV structural parameters: the proximal outflow tract 
from a parasternal short axis (RVOT1), distal outflow tract from a parasternal short 
axis (RVOT2), proximal outflow tract from a parasternal long axis (RVOTplax), basal 
inflow diameter (RVD1), mid inflow diameter (RVD2), base-to-apex length (RVD3) 
and RV end-diastolic area (RVDarea). In addition, the following functional RV 
parameters were extracted: fractional area change (RVFAC), tricuspid annular plane 
systolic excursion (TAPSE), peak systolic myocardial velocity (RVS’), peak early 
diastolic myocardial velocity (RVE'), peak late diastolic myocardial velocity (RVA'), 
peak global longitudinal strain (RV ε) and peak global systolic strain rate (RVSRS’). 
Demographic data of age, body surface area (BSA) and body mass index (BMI) were 
also collected. All relevant data were extracted directly from the 10 papers into a 
spreadsheet (Excel 2010, Microsoft Corp). Control and ARVC groups were coded 
discretely for each study. 
 
Statistical Analysis 
Continuous data for RV morphology and functional data were recorded as group 
mean ± SD for each study. Due to insufficient study numbers, RVOT2, RVOTplax, 
RVD1, RVD2, RVD3, RVA’ and RVSRS’ were not included in the meta-analysis but 
instead were assessed qualitatively. All statistical analysis was carried out with 
comprehensive meta-analysis software Version 3.3.070 (Biostat, Englewood, New 
Jersey, USA). A random effect meta-analysis model was used to quantify the 
weighted mean difference (WMD) (i.e. Difference in means) and 95% confidence 
intervals of ARVC group compared to control group allowing the production of 
parameter specific Forest Plots. To estimate or quantify the impact of between-study 
variation (heterogeneity) of the studies, I-squared and Tau squared were used 
20
.  Cut-
off values were established to provide clinically meaningful data utilising the pooled 
range data. Where there was overlap between groups a consensus approach was used 
which drew on the expertise of the working group. This is common practice in 
guideline development where ambiguous or inconclusive findings are evident 
21
 
 
RESULTS 
Baseline characteristics of the ARVC patients are summarized in Table 1 and 
characteristics of included studies in Table 2. The pooled mean data for the specific 
echocardiographic parameters, cut-off values and an assessment of heterogeneity are 
presented in Table 3. The meta-analysis highlighted a significantly larger RVOT1 
(P<0.00, 95% CI 3.649 to 7.112mm) and RVDarea (P<0.00, 95% CI 2.607 to 
7.060cm
2
) in the ARVC group compared to controls.  
 
INSERT TABLES 1, 2 AND 3 
 
RV functional data was significantly lower for RV ε (P<0.00, 95% CI 8 to 15%), 
RVFAC (P<0.00, 95% CI -11 to -6%), TAPSE (P<0.00, 95% CI -5.488 to -4mm), 
RVS' (P<0.00, 95% CI -3 to -2cm/s) and RVE' (P<0.00, 95% CI -5 to -2cm/s) (see 
Table 1). Exemplar Forest plots are presented in Figure 2.  
 
INSERT FIGURE 2 
 
DISCUSSION 
The main findings from this systematic review and meta-analysis are (1) there are 
significant differences in a range of structural and functional echocardiographic 
parameters between ARVC patients and healthy control participants, and (2) data 
from tissue Doppler and STE may represent useful additional tools when attempting 
to differentiate RV phenotype of ARVC patients from healthy controls.  
 
Right Ventricular Structure  
ARVC is a genetic disease that may present with atrophy of the RV myocardium, 
leading to aneurysmal dilation and wall motion abnormalities 
22,23
. Although this is a 
typical morphological pattern, the genotype-phenotype expression is variable often 
leading to heterogeneous structural adaptation 
24,25
. That aside, a ‘triangle of 
dysplasia’ in terms of both structure and function is frequently described which leads 
to localised dilation and dysfunction at the inflow tract (sinus), apex and RVOT 
26,27
 
or infundibulum (RVOT2) 
28
. Apical involvement is often seen in more advanced 
stages of the disease 
26,27
 and the RVOT is the most common starting point of non-
ischemic ventricular arrhythmias 
29
. This leads to the RVOT and/or inflow of the RV 
being the primary focus for early detection and subsequent serial assessment 
26
.   
The current echocardiographic component of the Task Force Criteria focuses on 
determining any localized structural dilatation of the outflow tract from either a short 
or long axis only. Data from the current systematic review and meta-analysis supports 
this. Interestingly we present no overlap in RVOT1 between controls and ARVC 
patients with a cut-off of 30 mm clearly discriminating between the two groups. This 
cut-off is lower than the current Task Force as well as the normative guidelines 
proposed by the American Society of Echocardiography (ASE) and raises the 
potential for a false negative result when using existing criteria.  Our data also 
demonstrate the importance of providing a holistic echocardiographic assessment of 
RV structure.  The enlarged RVDarea seen in ARVC patients compared to the healthy 
controls suggests that chamber enlargement occurs at the inflow and apex also.  The 
RVDarea cut-off based on our analysis is 19cm
2
 but this is much lower than the normal 
value as proposed by the ASE. This may be a consequence of the specific age-
matched control groups employed in the selected studies but clearly highlights the 
need for further clarification of normality.   
Due to an insufficient number of studies reporting data for RVD1 we were unable to 
conduct a meaningful meta-analysis on this parameter. Qualitative assessment of 
those few studies that did implement this parameter provides additional support for 
RV enlargement in ARVC patients. It is apparent that these additional parameters 
should be considered in conjunction with the outflow tract in order to better detail RV 
morphology in patients with ARVC. This supports the fundamental pathological 
mechanisms of disease progression and the known distribution of fatty infiltration.  
Right Ventricular Function 
Both major and minor Task Force criteria for ARVC include the presence of regional 
wall motion abnormalities and/or aneurysms 
9
. This clearly highlights the importance 
of functional RV wall degradation as part of the disease process. It is important to 
note that this is based on a subjective assessment which is dependent on operator 
experience as well as image quality. Subtle changes in function may be missed which 
could increase the risk of false negative findings 
30,31
. The current criteria also support 
an assessment of RVFAC, albeit this is only complementary and still must be in the 
presence of subjective regional wall motion abnormalities. Data from this meta-
analysis provides additional insight including an RVFAC cut-off at 42% compared to 
33% in the Task Force Criteria. Data from the matched controlled groups (n=217), 
however, did not present with values below 42% raising the question of what is 
considered normal.   
The complex nature of RV structure results in an equally complex “picture” related to 
function. In healthy individuals, RV ejection is predominantly driven by a 
combination of stored kinetic mechanics derived from gravity and inspiration as well 
as longitudinal shortening 
32
. It is has been demonstrated that this functional response 
may vary in different disease models in order to compensate for changes in the 
structural and functional integrity of the RV 
33,34
. In view of this a number of studies 
have assessed longitudinal RV function in ARVC utilizing TAPSE and TDI indices 
1,3,16,35
. These data highlight the potential for detection in the early stages of the 
disease 
1,3
 with a clear differential from healthy controls when using a 10 cm.s
-1
 cut-
off for systolic and diastolic myocardial tissue velocities. Aneq et al (2008), 
demonstrated that both TAPSE and systolic myocardial velocities were strong 
diagnostic parameters for ARVC but further highlight the superiority of TDI 
particularly in detecting ARVC at its early stage 
36,37
. Because of the inverse 
relationship between myocardial velocities and aging process 
38
, the risk of a false-
positive result for ARVC would increase with advancing age and hence caution is 
required when interpreting in older age groups. Consequently, addition of parameters 
of intrinsic RV myocardial indices (TDI) provides additional diagnostic and/or 
monitoring benefit over and above RVFAC alone. 
STE is a useful technique in the assessment of RV longitudinal function, with many 
studies demonstrating its value in variable disease states 
3,34,39
. In a study assessing the 
diagnostic utility of STE in ARVC it was observed that RV ε was the strongest 
independent predictor of cMR derived reduction in RV ejection fraction 
40
. In 
addition, Greiner et al. (2014) demonstrated that when screening 94 patients (13 with 
ARVC), RV ε provided additional diagnostic accuracy such that reduced false 
negative results were noted compared to the use of traditional echocardiographic 
parameters alone 
34
. In addition, both Sarvari et al. (2011) and Yoerger et al. (2005) 
reported that RV ε has the highest sensitivity and specificity for the diagnosis of 
ARVC
41,42
. In the current meta-analysis, global systolic ε was reported as an average 
of either the free wall and/or the RV portion of the septum. There were no ARVC 
patients demonstrating a peak RV ε above -21 % (n = 154); this is much lower than 
the currently accepted normal RV ε of -28% and lower than the control measure of -
29%. On this basis, RV ε may well provide additional value in the diagnosis and 
management of patients with ARVC.  
 
Clinical / Imaging Implications 
There is on-going debate in relation to the value of Task Force Criteria in ARVC 
43,44
Some authors noted a significant reduction in the sensitivity of the revised Task 
Force Criteria 
3,45
 and it has been suggested that false positive results may be a 
consequence of ‘‘over-interpretation’’ of subtle wall motion abnormalities (i.e. 
regional hypokinesia), which fall within the wide spectrum of normal RV function 
3,44
.  It is likely that the current Task Force Criteria are limited by the number of 
measures undertaken. Additional parameters highlighted in this meta-analysis may 
improve diagnostic accuracy.  Since, the current Task Force Criteria is based on a 
multi-disciplinary approach including clinical assessment, ECG, echocardiography, 
cMR, genetics and family history, any addition to the utilization of echocardiography 
needs to be made in this context and would likely add further corroborative 
information.  
 
Limitations and Future Directions 
Firstly, it is important to note that due to the nature of this type of study there is the 
real risk of methodological and selection bias and specifically related to blinding or 
non-blinding of outcome assessment. The homogeneity and heterogeneity values 
presented here highlight that this is only a minor effect however it is important to 
acknowledge this potential limitation when interpreting the findings.   
Due to the importance of establishing well-defined quality criteria, as well as the 
variable methods employed by individual studies, some of the standard RV 
echocardiographic indices were not incorporated into the meta-analysis. Future work 
in this area should consider standardizing echocardiographic methods for assessment 
of structure and function. The model of this study does not support a sensitivity or 
specificity analysis; this would be a sensible next step with our proposed cut-off data.   
We are now aware that ARVC is not just a disease of the RV. Recent studies have 
highlighted the gross and cellular impact on LV myocardial tissue 
3,22,26,46
.  Future 
work should continue to establish the extent and magnitude of LV involvement in 
ARVC and whether this can act as an important diagnostic or prognostic indicator.   
STE offers the potential to provide regional peak and time to peak ε data of RV wall 
segments.  However, few studies have attempted to incorporate this into their 
outcomes 
3,4,15,35,47
.  Data for all RV wall segments (i.e. basal and apical) as well as 
the temporal relationship between RV structure and function could provide additional 
diagnostic value. At this stage, it is important to note that although most of the studies 
reviewed utilized GE systems to acquire and analyze STE some studies did use other 
manufacturers. The presence of inter-vendor variability has been previously 
documented 
48
. It is clear that further work is required to develop consistent and valid 
RV ε data across platforms as well as further elucidating normality.   
 
Conclusion 
The data from this meta-analysis support Task Force Criteria for the diagnosis of 
ARVC. In addition, the inclusion of other measures of RV structure that better reflect 
the complex geometry may provide diagnostic value. Specifically, the application of 
TDI and myocardial ε in combination with RVFAC and TAPSE may also provide 
additional value in this setting. We recommend that future working groups consider 
this data when proposing new / revised criteria for the echocardiographic diagnosis of 
ARVC.  
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